l-cis-diltiazem; cyclic nucleotide-gated cation channels; dibutyryl-guanosine-3Ј5Ј-cyclic monophosphate; epithelial sodium ion channels; terbutaline ALVEOLAR FLUID CLEARANCE IS driven by vectorial Na ϩ transport across the alveolar epithelium (5, 10, 13, 16, 17, 19, 27, 30, 38, 39) . Na ϩ enters the alveolar epithelial cells through apically located Na ϩ channels and is subsequently extruded by basolaterally located Na ϩ -K ϩ -ATPases (for reviews, see Refs. 24, 26) . Increased levels of intracellular cAMP stimulate alveolar fluid clearance (3) . Substances that increase intracellular cAMP include epinephrine (10, 16, 30) and various other ␤-adrenergic agonists (5, 19, 30, 31, 38) . The mechanism by which intracellular cAMP stimulates alveolar fluid clearance is not fully understood, but cAMP could act in multiple ways, e.g., by recruiting Na ϩ -K ϩ -ATPases to cell membranes (31) , by recruiting Na ϩ channels [epithelial Na ϩ channels (ENaC)] to the apical membrane (35) , and/or by increasing the open probability of the Na ϩ channel (2, 3, 24, 26) . Also, recent data suggest that chloride may play a role in ␤-agonist-mediated upregulation of transport across alveolar epithelial type II cells (20) . Substances that do not interact with ␤-adrenergic receptors also regulate alveolar fluid clearance, e.g., corticosteroids (17, 29) and growth factors (19, 36, 38) .
In several animal species, the Na ϩ channel blocker amiloride inhibited a significant fraction of unstimulated and stimulated alveolar fluid clearance (5, 10, 13, 16, 17, 19, 30, 38, 39) . The amiloride sensitivity may be related to the ENaC (2, 16, 29, 38, 39) and possibly also to nonspecific cation channels (23, 37) . In contrast, the amiloride-insensitive fraction of alveolar fluid clearance and Na ϩ absorption is less well understood. Some recent studies demonstrated that the amiloride-insensitive fraction of 8-bromo-cGMP-stimulated short-circuit current and 22 
Na
ϩ uptake in rat tracheal epithelia was inhibited by dichlorobenzamil or l-cis-diltiazem, which are both inhibitors of cyclic nucleotide-gated cation (CNG) channels (33) . In subsequent studies, dichlorobenzamil inhibited a significant fraction of lung fluid absorption in sheep (21) , which suggested that CNG channels play a role in alveolar fluid absorption. The CNG channels were originally identified and cloned from vertebrate rod photoreceptors (15) and the olfactory neuroepithelium (28) . Three different CNG channel isoforms have been cloned (6) . The CNG1 channel has a wide tissue distribution and is localized to eye, brain, thymus, heart, and lung (12) . In the lung, mRNA for CNG1 has been localized to the distal lung epithelium and mainly to alveolar epithelial cells.
We hypothesized that the amiloride-insensitive fraction of alveolar fluid clearance in the rat is, at least partly, mediated through the CNG channels. Therefore, our first aim was to investigate the functional contributions of amiloride-sensitive Na ϩ channels and amiloride-insensitive CNG channels for alveolar fluid clearance under unstimulated conditions. Because CNG channels are stimulated by cyclic nucleotides and ␤-adrenergic agonists act through the increase of both intracellular cAMP and cGMP (32), our second aim was to investigate amiloride-sensitive and amiloride-insensitive fractions of alveolar fluid clearance after ␤-adrenergic stimulation. Our third aim was to investigate whether direct intrapulmonary instillation of dibutyryl-cGMP (DBcGMP) stimulated alveolar fluid clearance and to study amiloride-sensitive and amilorideinsensitive fractions of alveolar fluid clearance after DBcGMP instillation.
MATERIALS AND METHODS

Animals
Adult male Sprague-Dawley rats (n ϭ 69), weighing 275-350 g (B&K Universal, Sollentuna, Sweden), were used. The rats were kept at a 12:12-h day-night rhythm and had free access to standard rat chow (R 3; Astra-Ewos, Södertä lje, Sweden) and tap water. The Ethical Review Committee on Animal Experiments at Lund University approved the experiments.
Preparation of Solutions
A 5% albumin instillate solution was prepared by dissolving 50 mg/ml bovine serum albumin (Sigma Chemical, St. Louis, MO) in 0.9% NaCl (Pharmacia-UpJohn, Uppsala, Sweden). In some studies, 10
Ϫ4 M terbutaline hemisulfate (terbutaline; Sigma Chemical) or 10 Ϫ4 M DBcGMP (Sigma Chemical) plus 10 Ϫ4 M aminophylline (Sigma Chemical) were added to the albumin solution. Also, 10 Ϫ3 M amiloride hydrochloride hydrate (amiloride; Sigma Chemical) and/or 10 Ϫ3 M l-cis-diltiazem hydrochloride (l-cis-diltiazem; Research Biochemicals, Natick, MA) were added to the instillate solution in some studies. For the DBcGMP studies, an aminophylline infusion solution (10 Ϫ4 M in 0.9% NaCl) was prepared.
Surgical Procedure and Ventilation
The rats were anesthetized by an intraperitoneal injection of pentobarbital sodium (50 mg/kg body wt; Apoteksbolaget, Umeå, Sweden). A 2.0-mm (ID) endotracheal tube (PE-240, Clay Adams, Becton Dickinson, Sparks, MD) was inserted through a tracheotomy, and a 0.58-mm (ID) catheter (PE-50, Clay Adams, Becton Dickinson) was inserted in the left carotid artery. Another PE-50 catheter was inserted in the left jugular vein for administration of aminophylline during the DBcGMP studies. Pancuronium bromide (0.3 mg ⅐ kg body wt Ϫ1 ⅐ h Ϫ1 ; Pavulon, Organon Teknika, Boxtel, The Netherlands) was administered through the arterial catheter for neuromuscular blockade. Pupil dilatation, blood pressure, and heart rate were used as indicators of anesthesia. The anesthesia was complemented when necessary, e.g., if blood pressure began to increase significantly. The rats were maintained in the left lateral decubitus position during the experiment and were ventilated with a constant-volume piston pump (Harvard Apparatus, Nantucket, MA) with an inspired oxygen fraction of 1.0 and tidal volumes set to reach peak airway pressures of 10-12 cmH 2 O during the baseline period. Positive end-expiratory pressure was kept at 2-3 cmH 2 O.
Peak airway pressure, arterial blood pressure, and heart rate were measured with calibrated pressure transducers (UFI model 1050BP or TSD104, BioPac Systems, Goleta, CA) connected to analog-to-digital converters and amplifiers (MP100 and DA100, respectively, BioPac Systems) and continuously recorded with Acknowledge 3.2 software (BioPac Systems) on an IBM PC-compatible computer.
General Protocol
After a 30-min baseline period of stable heart rate and blood pressure, the instillation tubing (PE-50) was passed through the tracheal tube into the left lung without interrupting ventilation. The instillation solution (3-4 ml/kg body wt) was instilled over 25 min by infusing 0.04 ml/min with a 1-ml syringe. The study proceeded over 1 h and started at the beginning of fluid instillation. After instillation, the tubing was withdrawn. For the DBcGMP studies, a bolus dose of 0.56 mg/kg body wt aminophylline in 0.4 ml was injected through the vein catheter 5 min before instillation. Every 12 min until 48 min after the start of the experiment, the initial aminophylline dose was complemented with 21 mg/kg body wt aminophylline in 0.15 ml of the infusion solution. This protocol gave a total dose of 140 mg ⅐ kg body wt Ϫ1 ⅐ h Ϫ1 . At the end of the experiment, a blood sample (2 ml) was withdrawn from the carotid artery. The abdomen was opened, and the rats were exsanguinated by transection of the renal artery. The lungs were removed from the chest through a midline sternotomy. A PE-50 catheter was passed into the instilled lung, and a sample of the remaining alveolar fluid was collected. A previous study demonstrated that the protein concentration in fluid aspirated with a catheter wedged into the distal air spaces is a good reflection of the alveolar fluid protein concentration (4) . Protein concentrations in the instilled solutions and in the final alveolar fluid samples were measured spectrophotometrically (iEMS reader MF, Labsystems, Helsinki, Finland) with the Lowry method (22) adapted for microtiter plates.
Specific Protocol
All rats were surgically prepared as described above. The rats were randomly divided into the following groups. All rats were studied for 1 h as described in General Protocol.
Control studies. The rats (n ϭ 6) were instilled with the 5% albumin.
Terbutaline studies. The rats (n ϭ 6) were instilled with the 5% albumin solution containing 10 Ϫ4 M of the ␤-adrenergic agonist terbutaline.
DBcGMP studies. The rats (n ϭ 5) were instilled with the 5% albumin solution containing 10 Ϫ4 M of the membranepermeable cGMP analog DBcGMP plus 10 Ϫ4 M aminophylline. Aminophylline was added to the instillate to prevent hydrolysis of DBcGMP. When DBcGMP was instilled, aminophylline was given intravenously during the 1-h study. To test that aminophylline did not affect alveolar fluid clearance by itself, another group (n ϭ 3) with 10 Ϫ4 M aminophylline added to the albumin solution was studied.
l-cis-Diltiazem studies. The rats were instilled with the 5% albumin solution containing 10 Ϫ3 M of the CNG channel
Ϫ4 M terbutaline (n ϭ 5). Another group of rats was instilled with 5% albumin solution containing 10
Amiloride studies. The rats were instilled with the 5% albumin solution containing 10 Ϫ3 M of the sodium channel inhibitor amiloride (n ϭ 6) or 10 Ϫ3 M amiloride plus 10 Ϫ4 M terbutaline (n ϭ 4). Another group of rats was instilled with 5% albumin solution containing 10 Ϫ3 M amiloride plus 10
Ϫ4
M DBcGMP plus 10 Ϫ4 M aminophylline (n ϭ 5). l-cis-Diltiazem plus amiloride studies. The rats were instilled with the 5% albumin solution containing 10 Ϫ3 M l-cis-diltiazem plus 10 Ϫ3 M amiloride (n ϭ 6) or containing 10 Ϫ3 M l-cis-diltiazem plus 10 Ϫ3 M amiloride plus 10 Ϫ4 M terbutaline (n ϭ 7). Another group of rats was instilled with 5% albumin solution containing 10 Ϫ3 M l-cis-diltiazem plus 10 Ϫ3 M amiloride plus 10 Ϫ4 M DBcGMP plus 10 Ϫ4 M aminophylline (n ϭ 5).
Alveolar Fluid Clearance Analysis
Alveolar fluid clearance was calculated from the increase in alveolar albumin concentration over the 1-h study, as has been done in several studies before (10, 16, 17, 29, 30) . Data are presented in two ways. First, alveolar fluid clearance is presented as the final-to-instilled protein concentration ratio, i.e., the ratio of the final alveolar fluid sample protein concentration over the instilled protein concentration. This provides direct evidence for clearance of excess fluid from the distal air spaces. Because there were no changes in epithelial protein permeability in any experimental group and little protein left the air spaces, the increase in protein concentration over 1 h is caused by water leaving the air spaces (data not shown). The second way of presenting the data is by calculating alveolar fluid clearance (AFC) by the following equation
where V I is the instilled fluid volume and V F is final alveolar fluid volume calculated from the increase in protein concentration over the 1-h experimental time period
where C F and C I are the protein concentrations of the final alveolar fluid and the instilled fluid, respectively.
Calculation of Fractional Inhibition of Alveolar Fluid Clearance
The fractional inhibition of alveolar fluid clearance by amiloride and l-cis-diltiazem under control or stimulated conditions was calculated by the following equation
where AFC 0 is alveolar fluid clearance under control or stimulated conditions (i.e., without inhibitors) and AFC I is alveolar fluid clearance when the inhibitors (amiloride or l-cis-diltiazem or both) were added to the instillate.
Alveolar Fluid Clearance Composition
Alveolar fluid clearance was also analyzed with respect to absolute alveolar fluid clearance (%), which constituted the alveolar fluid clearance that was sensitive to amiloride or l-cis-diltiazem. The amiloride-sensitive alveolar fluid clearance was calculated as the difference between control (or stimulated) alveolar fluid clearance and the alveolar fluid clearance after amiloride inhibition. To compensate for overlapping inhibition by the two drugs, we calculated the l-cisdiltiazem-sensitive fraction as alveolar fluid clearance after amiloride plus l-cis-diltiazem inhibition subtracted from alveolar fluid clearance after amiloride inhibition.
Statistics
Data are summarized and presented as means Ϯ SD. The data were analyzed by one-way ANOVA with Tukey's test post hoc. Differences were considered significant when a P value of Ͻ0.05 was obtained.
RESULTS
Influence of CNG Channel Inhibitors Under Unstimulated Conditions
We investigated the effect of the CNG channel inhibitor l-cis-diltiazem on the unstimulated alveolar fluid clearance (control) in adult ventilated rats. When 10
Ϫ3
M l-cis-diltiazem were added to the 5% albumin solution, no inhibition of control alveolar fluid clearance was observed (Fig. 1, Table 1 ). On the other hand, amiloride (10 Ϫ3 M) significantly inhibited alveolar fluid clearance by 46 Ϯ 15%. The combination of amiloride and l-cis-diltiazem had no additive effect ( Table 1) .
Influence of CNG Channel Inhibition Under Terbutaline Stimulation
We then investigated whether terbutaline stimulation (10 Ϫ4 M) of alveolar fluid clearance altered the composition of amiloride-sensitive and amiloride-insensitive pathways of fluid clearance from the distal air spaces. Terbutaline stimulated alveolar fluid clearance by 85 Ϯ 6% over control conditions, a result similar to previous studies in the rat (17, 38) . Amiloride inhibited alveolar fluid clearance under stimulated conditions and returned the clearance to control levels ( Fig. 2, Table 1 ). When l-cis-diltiazem was added to the instillate, the alveolar fluid clearance again similarly decreased to control levels, i.e., the terbutaline stimulation was completely abolished (Fig. 2 , Table  1 ). Amiloride and l-cis-diltiazem administered together further decreased alveolar fluid clearance to below control levels (Fig. 2, Table 1 ).
Influence of CNG Channel Inhibition Under DBcGMP Stimulation
It was not previously known if alveolar fluid clearance could be stimulated by cGMP. Therefore, we studied alveolar fluid clearance after instillation of a membrane-permeable cGMP analog. Addition of DBcGMP to the instilled fluid significantly increased alveolar fluid clearance by 36 Ϯ 5% compared with control rats (Fig. 3, Table 1 ). However, DBcGMP at this concentration (10 Ϫ4 M) did not increase alveolar fluid clearance as effectively as terbutaline did (Table 1) . Because the CNG channels are activated by cGMP (6), we investigated whether inhibition of alveolar fluid clearance by l-cis-diltiazem was altered after simultaneous administration of DBcGMP. Both l-cis-diltiazem and amiloride inhibited the cGMP-stimulated alveolar fluid clearance to control levels (Fig. 3) . The combination of l-cis-diltiazem and amiloride was additive, because the combination of both inhibitors decreased the cGMPstimulated alveolar fluid clearance to levels significantly below control alveolar fluid clearance (Fig. 3) .
Fractional Inhibition of Alveolar Fluid Clearance
The fractional inhibition of alveolar fluid clearance by the channel blockers amiloride and l-cis-diltiazem was calculated for both the control and stimulated conditions (Table 1; Fig. 1) . Amiloride was the most effective inhibitor of alveolar fluid clearance under control conditions, whereas l-cis-diltiazem had no inhibitory effect on control alveolar fluid clearance.
When alveolar fluid clearance was stimulated by terbutaline, both blockers significantly inhibited alveolar fluid clearance. The most dramatic change was with l-cis-diltiazem, which, during control conditions, had no inhibitory effect on alveolar fluid clearance but, during terbutaline-stimulated conditions, inhibited ϳ50% of the alveolar fluid clearance. The combination of amiloride and l-cis-diltiazem increased the fractional inhibition to ϳ80%, which was greater than that of either of the inhibitors given alone (Table 1) .
On stimulation of alveolar fluid clearance with DBcGMP, l-cis-diltiazem inhibited ϳ25% of alveolar fluid clearance (Table 1) . On the other hand, amiloride inhibited only ϳ30% of alveolar fluid clearance, which was less than control or terbutaline-stimulated alveolar fluid clearance. l-cis-Diltiazem and amiloride in combination were additive and inhibited a larger fraction (ϳ50%) of alveolar fluid clearance compared with the administration of each drug alone.
Ratio of Amiloride-sensitive and -insensitive Alveolar Fluid Clearance
The amiloride-sensitive and l-cis-diltiazem-sensitive (amiloride-insensitive) components of alveolar fluid clearance are illustrated in Fig. 4 . After stimulation with terbutaline, the amiloride-sensitive component increased twofold compared with control rats, whereas the amiloride-insensitive component increased fivefold. After DBcGMP stimulation, the amiloride-sensitive component remained unchanged, whereas the amiloride-insensitive component increased threefold compared with control rats. The component that was insensitive to either of the drugs remained constant, irrespective of treatment.
Airway Pressure and Hemodynamics
Airway pressure did not vary within groups or between groups during the experiments. Blood pressure increased Ͻ22% from baseline during the initial phase of instillation in all groups but returned to baseline values within 5-10 min. Furthermore, blood pressure varied Ͻ18% among groups at any given time point. Heart rate never varied by Ͼ12% within groups over the experimental time period and by Ͻ13% among groups at any given time point. At the end of the experiment, the hematocrit was always within the normal range and varied Ͻ11% within groups and Ͻ13% among groups.
DISCUSSION
Based on several in vivo studies in several different animal species, amiloride inhibits 30-90% of alveolar fluid clearance (1, 5, 10, 13, 16, 17, 19, 21, 29, 30, 38, 39) . In the rat, 45% is amiloride sensitive; the amiloride-insensitive fraction of alveolar fluid clearance has not been fully investigated. In this study, we hypothesized that part of the amiloride-insensitive fraction of alveolar fluid clearance in adult rats was mediated through the CNG channel that has been localized to the adult rat lung (12) . The CNG channels have also recently been shown to play a role in the clearance of alveolar fluid in sheep (21) . Therefore, we used the CNG channel blocker l-cis-diltiazem to evaluate the contribution of these channels to alveolar fluid clearance under normal and stimulated conditions in rats.
We used relatively high doses of amiloride and l-cisdiltiazem (10 Ϫ3 M). We selected these concentrations because both l-cis-diltiazem and amiloride are lowmolecular-weight compounds and amiloride has previously been used at this concentration in several studies of in vivo alveolar fluid clearance (1, 5, 10, 16, 17, 29, 30, 38, 39) . Also, it has been demonstrated that a fraction of amiloride binds to albumin and another fraction leaves the air spaces rapidly because of the small molecular size (39) . Therefore, although a relatively high concentration is added, the effective in vivo concentrations were probably much lower.
Amiloride inhibited 40-50% of alveolar fluid clearance under normal and stimulated conditions, an inhibition well in accordance with what has been reported previously in the rat (10, 17, 19, 38, 39) . l-cis-Diltiazem Fig. 4 . Absolute contribution of amiloride-sensitive pathways and l-cis-diltiazem-sensitive pathways to alveolar fluid clearance in rats under control, terbutaline-stimulated, and DBcGMP-stimulated conditions. The l-cis-diltiazem-sensitive component was estimated when it was administered with amiloride. The absolute components that were not affected by either of the drugs (unknown pathways) were similar during all conditions. Terbutaline stimulation increased the l-cis-diltiazem-sensitive pathways by 5-fold, but the amiloride-sensitive fraction was increased only 2-fold. After DBcGMP stimulation, only the l-cis-diltiazem-sensitive component of alveolar fluid clearance was affected (a 3-fold increase).
lacked an inhibitory effect when it was added to the instilled fluid under control conditions, whereas this drug decreased the terbutaline-stimulated alveolar fluid clearance to a level similar to that of amiloride. When l-cis-diltiazem was administered together with amiloride, an almost complete blockade of alveolar fluid clearance was observed. This result suggests that terbutaline stimulation recruits or activates pathways for alveolar fluid clearance in addition to, and perhaps different from, the ENaC, possibly CNG channels. These inhibitor studies cannot exclude the possibility that l-cis-diltiazem may act on the same pathway as amiloride does. However, because l-cis-diltiazem did not inhibit control alveolar fluid clearance, this result supports the hypothesis that terbutaline stimulation activates or recruits an amiloride-insensitive Na ϩ transporting pathway of alveolar fluid clearance. Alternatively, terbutaline may have altered the constitution of ENaC, making the ENaC channel sensitive to l-cisdiltiazem. In fact, there are reports suggesting that ENaC structure may be changed under certain conditions, and thus amiloride sensitivity could be altered (9) . Also, in a mutation of ENaC causing pseudohypoaldosteronism, the amiloride sensitivity was significantly reduced (7). However, because l-cis-diltiazem is an inhibitor of the CNG channel, it is more likely that terbutaline recruited or activated CNG channels in the distal lung epithelium together with amiloride-sensitive pathways.
When alveolar fluid clearance was stimulated with terbutaline, the fractional inhibition (presented as percentage of stimulated alveolar fluid clearance) by amiloride was not significantly altered compared with control conditions (Table 1 ). In contrast, the fractional inhibition by amiloride after DBcGMP stimulation decreased compared with control conditions. These results indicate that the composition of amiloride-sensitive and l-cis-diltiazem-sensitive pathways for alveolar fluid clearance was altered differently after stimulation by terbutaline and DBcGMP, respectively. Because of this, we presented the effect of the inhibitors as a component of each pathway. We calculated the composition of alveolar fluid clearance that represents each pathway (amiloride sensitive, l-cis-diltiazem sensitive, and noninhibited pathways) (Fig. 4) . With this approach, there were differences among control, terbutaline-stimulated, and DBcGMP-stimulated conditions. As shown in Fig. 4 , the amiloride-sensitive component increased twofold after terbutaline stimulation compared with control, but the fractional percentage of inhibition by amiloride remained unchanged because the alveolar fluid clearance also doubled (Table 1) . Corresponding calculations for l-cis-diltiazem inhibition after terbutaline stimulation, compared with control conditions, gave a fivefold increase in inhibition. These data suggest that terbutaline might have recruited similar absolute components of amiloride-sensitive and l-cis-diltiazem-sensitive pathways for alveolar fluid clearance in the rat. However, after DBcGMP stimulation of alveolar fluid clearance, the l-cis-diltiazem-sensitive alveolar fluid clearance increased by threefold, which was less than the increase after terbutaline stimulation. By contrast, the amiloride-sensitive alveolar fluid clearance remained unchanged after DBcGMP stimulation.
On balance, the results suggest that both amiloridesensitive sodium channels and CNG channels were activated after terbutaline stimulation of alveolar fluid clearance in the rat, because amiloride and l-cis-diltiazem both inhibited alveolar fluid clearance. By contrast, after DBcGMP stimulation of alveolar fluid clearance, only the l-cis-diltiazem-sensitive component of alveolar fluid clearance increased. In view of these results and because terbutaline may increase both intracellular cGMP and cAMP (32) , the results suggest that terbutaline may have stimulated alveolar fluid clearance in two different ways. First, cGMP may stimulate alveolar fluid clearance by activation of CNG channels. Second, an amiloride-sensitive fraction of alveolar fluid clearance (probably mostly ENaC) is mediated through intracellular cAMP (3, 16, 19, 30) .
Because other stereoisomers of diltiazem are inhibitors of the voltage-gated Ca 2ϩ channel and because CNG channels can cause Ca 2ϩ influx (32) , it is also possible that l-cis-diltiazem affected intracellular Ca 2ϩ levels. Terbutaline activates amiloride-sensitive Na ϩ uptake in isolated fetal distal lung epithelial cells (37) and adult epithelial alveolar type II cells (14) in a way that may involve increased intracellular Ca 2ϩ concentration. Such an increase could be mediated through uptake of extracellular Ca 2ϩ via Ca 2ϩ channels and/or recruitment from intracellular stores. If l-cis-diltiazem inhibits Ca 2ϩ channels, the inhibition of alveolar fluid clearance by l-cis-diltiazem after terbutaline stimulation could occur because terbutaline fails to stimulate ENaC recruitment and/or activation because of the inability of terbutaline to increase intracellular Ca 2ϩ . A certain fraction of alveolar fluid clearance is not inhibited by either amiloride or l-cis-diltiazem under control conditions or after stimulation. This fraction of alveolar fluid clearance may be explained in at least three possible ways. First, a third yet unidentified Na ϩ -specific channel or a nonspecific cation channel could mediate this fraction of alveolar fluid clearance. Several reports have suggested the existence of different cation channels in the alveolar epithelium (for review, see Ref. 24) . However, most of these channels are inhibited by amiloride at the concentrations used in this study and would, therefore, probably be included in the fraction of alveolar fluid clearance that is sensitive to amiloride. Second, transport of Cl Ϫ across the alveolar epithelium could also contribute to the driving of water from the air spaces. It has been suggested that the cystic fibrosis transmembrane conductance regulator channel may regulate absorption of Na ϩ in the adult lung (20) . There is also preliminary evidence that the bumetanide-sensitive 2Cl Ϫ -Na ϩ -K ϩ cotransporter might be involved in stimulated alveolar fluid clearance (18) . Third, passive forces, i.e., nonmetabolic pathways, could constitute part of the unstimulated alveolar fluid clearance mechanism. However, this pathway is probably very small, especially in the in vivo lung, compared with the active pathway (27) . Therefore, it is likely that the remaining alveolar fluid clearance after amiloride or l-cis-diltiazem inhibition is mediated through still unknown pathways. In this study, 48 Ϯ 3% of alveolar fluid clearance could be inhibited by amiloride and 48 Ϯ 21% by l-cis-diltiazem after ␤-adrenergic stimulation. In various in vitro preparations (single cells or monolayers of alveolar epithelial type II cells or fetal distal lung epithelial cells), up to 100% of Na ϩ channel activity can be inhibited with amiloride (for review, see Ref. 24) . The discrepancy between the in vivo and in vitro situation might be explained by heterogeneous distribution of different Na ϩ or cation channels in the alveolar epithelium as well as by cellular changes after isolation and culture conditions. Previously, it was demonstrated that the CNG1 channel was located mainly in the alveolar epithelial cells of the lung (12) . ␣-ENaC mRNA and ENaC protein have been localized primarily to the alveolar epithelial type II cells in the deep lung and to airway epithelial cells in adult rats (25) . Consequently, as suggested previously (33) , if the l-cisdiltiazem-sensitive CNG1 channels were located primarily on alveolar epithelial type I cells and the amiloride-sensitive ENaC were located primarily on the alveolar type II cells, then this could explain why amiloride does not inhibit 100% of alveolar fluid clearance in vivo in most species. In contrast to the alveolar type II cell preparations, the in vivo condition also includes alveolar type I cells. Hence, significant portions of amiloride-insensitive Na ϩ (or cation) channels in the alveolar type I cells would not be included in those alveolar type II cell preparations and, therefore, could explain why amiloride fails to inhibit Ͼ40% of alveolar fluid clearance in the in vivo lung. Thus terbutaline may increase ENaC activity or the quantity of active ENaC in the membrane of the alveolar type II cells simultaneously with activation of CNG1. It has, however, been suggested that ENaC could be present in alveolar epithelial type I cells also (8) . Our hypothesis that a primary localization of CNG1 channels to the alveolar type I cells and that these channels mediate a fraction of stimulated alveolar fluid clearance is also supported by the fact that guanylate cyclase exists in alveolar type I cells (34) , where the CNG1 mRNA is abundantly expressed (12) .
Vectorial transport of ions requires an entry step at the apical cell membrane and an exit step at the basolateral cell membrane. In the alveolar epithelium, the entry step is ENaC and the exit step is the basolateral Na ϩ -K ϩ -ATPase. In this study, we focused our work on apical amiloride-sensitive and -insensitive Na ϩ channels and their role in driving alveolar fluid clearance in adult rat lungs. It is likely that both the apical entry step (Na ϩ channels) and the basolateral exit step (Na ϩ -K ϩ -ATPase) are linked to be able to accommodate changes in fluid transport across the alveolar epithelium. Although not studied here, effects of l-cisdiltiazem or amiloride on the lung epithelial Na ϩ -K ϩ -ATPase function cannot be ruled out. There is some evidence that the Na ϩ -K ϩ -ATPase function is upregulated by ␤-adrenergic agonists and cGMP-dependent protein kinases (11, 31) . Although it is more likely that l-cis-diltiazem inhibits CNG channels, limited inhibitory effects on the basolateral Na ϩ -K ϩ -ATPase cannot be ruled out.
We conclude that, under normal conditions in in vivo rat lungs, Na ϩ -driven alveolar fluid clearance is mediated through amiloride-sensitive pathways, probably ENaC, and a yet incompletely characterized amilorideinsensitive pathway. Stimulation with terbutaline may recruit or activate both ENaC and CNG channels in the alveolar epithelium, resulting in an increased alveolar fluid clearance. Terbutaline could act by increasing intracellular cAMP, stimulating ENaC channels (3, 16, 19, 30) , and also increasing intracellular cGMP, thus stimulating CNG channels in the alveolar epithelium.
